Morgan Stanley Reiterates Equal-Weight on Nautilus Biotechnology, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Tejas Savant has reiterated an Equal-Weight rating on Nautilus Biotechnology (NASDAQ:NAUT) and maintained a $6 price target.

August 04, 2023 | 1:48 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has reiterated an Equal-Weight rating on Nautilus Biotechnology and maintained a $6 price target.
The news is directly about Nautilus Biotechnology and is likely to have a neutral impact on its stock price in the short term. The Equal-Weight rating suggests that the stock is expected to perform in line with the market or other stocks in its sector. The maintained price target indicates that the analyst's valuation of the company has not changed.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100